Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas” or the “Company”), announces that it has entered into a definitive stock purchase agreement (the “Stock Purchase Agreement”) to sell Matinas BioPharma Nanotechnologies, Inc., including MAT2203 and the Company’s lipid nano-crystal (“LNC”) technology platform, to Azurity Pharmaceuticals, Inc. (“Azurity”). Azurity will acquire Matinas BioPharma Nanotechnologies, Inc., including all rights to MAT2203 and Matinas’s LNC technology platform, for $4.0 million in upfront cash consideration, subject to customary adjustments, plus up to an additional $17.5 million in potential milestone payments and future mid-single-digit royalties on net sales and certain licensing proceeds generated by MAT2203.
Read the full article: Matinas BioPharma Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate to Azurity Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2026/07/13/3326126/32419/en/matinas-biopharma-announces-strategic-business-combination-with-gh-power-to-create-publicly-traded-advanced-clean-energy-and-green-hydrogen-company-signs-definitive-agreement-to-se.html?_gl=1*7tb6tc*_up*MQ..*_ga*MTIwMTc2MjQuMTc4Mzk0NDQyNQ..*_ga_B6167QB2TF*czE3ODM5NDQ0MjQkbzEkZzAkdDE3ODM5NDQ0MjQkajYwJGwwJGg3NDU5ODg3NTg.*_ga_ERWPGTJ5X8*czE3ODM5NDQ0MjQkbzEkZzAkdDE3ODM5NDQ0MjQkajYwJGwwJGgw